(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 November 2024 (14.11.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/231809 A1

(51) International Patent Classification:
C07K 14/705 (2006.01) *A61P 37/00* (2006.01)
A61P 25/28 (2006.01) *A61K 38/00* (2006.01)

(21) International Application Number:
PCT/IB2024/054338

(22) International Filing Date:
03 May 2024 (03.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2306711.9 05 May 2023 (05.05.2023) GB

(71) Applicant: **DUCENTIS BIOTHERAPEUTICS LIMITED** [GB/GB]; Suite 2, First Floor, 10 Temple Back, Bristol BS1 6FL (GB).

(72) Inventor: **ASHFIELD, Rebecca**; c/o Ducentis Biotherapeutics Limited, Suite 2, First Floor, 10 Temple Back, Bristol BS1 6FL (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

(54) Title: CD200 FUSION PROTEINS

Fig. 17



(57) Abstract: The invention relates to fusion proteins comprising a mutated CD200 portion comprising K130 and I131 mutations which binds with greater affinity to the human CD200 receptor than wild-type CD200, directly fused to a non-CD200 portion having improved pharmacokinetic profile. The invention also relates to a polynucleotide encoding the fusion protein, a pharmaceutical composition comprising it and uses thereof.

[Continued on next page]

WO 2024/231809 A1

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*